

Acute myocardial infarction

Diagnosis and prehospital care

Dr Navid Reza Mashayekhi

Arak university of medical sciences

- The outcomes of patients suffering from acute myocardial infarction are contingent on the time taken to deliver definitive treatment.
- Evidence has shown that the extent of myocardial salvage is greatest if patients are reperfused in the first 3 h from the onset of symptoms

- For every 30-min delay in coronary reperfusion, the relative 1-year mortality rate increases by 7.5%

delays in reperfusion

- prehospital setting:
- the time from the onset of symptoms to first medical contact (FMC)
- the time from FMC to diagnosis and then reperfusion treatment—termed ‘system delay’.


First Medical Contact

- First medical contact (FMC) is the time at which trained EMS providers who can obtain and interpret the ECG arrive at the patient's side

Ideally less than 10 min from FMC, EMS providers should activate the ‘STEMI pathway’ in which patients may be transferred to a center capable of primary PCI, a non-PCI center for fibrinolysis, or receive prehospital fibrinolysis during transfer.

- local protocols that facilitate prehospital registration may be in place to transfer patients directly to the catheterization lab, effectively bypassing the emergency department and further reducing unnecessary delays.

Modes of patient presentation, components of ischaemic time and flowchart for reperfusion strategy selection



- Caution should be exercised concerning overdependence on primary PCI where facilities may not be within reasonable accessibility.

Diagnosis of Myocardial Infarction

elevated blood serum levels of cardiac enzymes (preferably cardiac troponin) and one or more of the following:

1. symptoms suggestive of myocardial ischemia
2. ECG demonstrating new significant ST-T changes or new left bundle branch block (LBBB),
3. new pathological Q waves on ECG
4. imaging evidence of new loss of viable myocardium or new regional wall motion abnormality
5. identification of intracoronary thrombus on angiography or autopsy




Figure 1
Diagnostic algorithm and triage in acute coronary syndrome.

Table 1 Clinical implications of high-sensitivity cardiac troponin assays (1)

Compared with standard cardiac troponin assays, hs-cTn assays:

- Have higher NPV for AMI.
- Reduce the 'troponin-blind' interval leading to earlier detection of AMI.
- Result in ~4% absolute and ~20% relative increases in the detection of type 1 MI and a corresponding decrease in the diagnosis of unstable angina.
- Are associated with a 2-fold increase in the detection of type 2 MI.

Table 1 Clinical implications of high-sensitivity cardiac troponin assays (cTn) (2)

Levels of hs-cTn should be interpreted as quantitative markers of cardiomyocyte damage (i.e. the higher the level, the greater the likelihood of MI):

- Elevations beyond 5-fold the upper reference limit have high (>90%) PPV for acute type 1 MI.
- Elevations up to 3-fold the upper reference limit have only limited (50–60%) PPV for AMI and may be associated with a broad spectrum of conditions.
- It is common to detect circulating levels of cTn in healthy individuals.

Rising and/or falling cTn levels differentiate acute (as in MI) from chronic cardiomyocyte damage (the more pronounced the change, the higher the likelihood of AMI).



1

TYPE 1 MYOCARDIAL INFARCTION

Spontaneous myocardial infarction related to ischaemia due to a primary coronary event such as plaque erosion and/or rupture, fissuring or dissection



2

TYPE 2 MYOCARDIAL INFARCTION

Myocardial infarction secondary to ischaemia due to either increased oxygen demand or decreased supply



3

TYPE 3 MYOCARDIAL INFARCTION

Sudden unexpected cardiac death often with symptoms suggestive of myocardial ischaemia



4

TYPE 4 MYOCARDIAL INFARCTION

Myocardial infarction associated with percutaneous coronary intervention (4a) or stent thrombosis (4b)



5

TYPE 5 MYOCARDIAL INFARCTION

Myocardial infarction associated with cardiac surgery




Injury

MYOCARDIAL INJURY

Multifactorial aetiology; acute or chronic based on change in cardiac troponin concentrations with serial testing

Figure 2 Value of high-sensitivity cardiac troponin.



hs-cTn assays (right) are reported in ng/L and provide identical information as conventional assays (left, reported in µg/L) if the concentration is substantially elevated, e.g. above 100 ng/L. In contrast, only hs-cTn allows a precise differentiation between 'normal' and mildly elevated. Therefore, hs-cTn detects a relevant proportion of patients with previously undetectable cardiac troponin concentrations with the conventional assay who have hs-cTn concentrations above the 99th percentile possibly related to AMI.

?? = unknown due to the inability of the assay to measure in the normal range

^aThe limit of detection varies among the different hs-cTn assays between 1 ng/L and 5 ng/L. Similarly, the 99th percentile varies among the different hs-cTn assays, mainly being between 10 ng/L and 20 ng/L.




Figure 3 (1)
0 h/1 h rule-out and rule-in algorithm using high-sensitivity cardiac troponin assays in haemodynamically stable patients presenting with suspected non-ST-segment elevation acute coronary syndrome to the emergency department.

^aOnly applicable if CPO >3 h.

Table 2 Conditions other than acute type 1 myocardial infarction associated with cardiomyocyte injury (= cardiac troponin elevation) (1)

Tachyarrhythmias

Heart failure

Hypertensive emergencies

Critical illness (e.g. shock/ sepsis/ burns)

Myocarditis^a

Takotsubo syndrome

Valvular heart disease (e.g. aortic stenosis)

Aortic dissection

Pulmonary embolism, pulmonary hypertension

Renal dysfunction and associated cardiac disease

Bold = most frequent conditions. ^aIncludes myocardial extension of endocarditis or pericarditis.

Table 2 Conditions other than acute type 1 myocardial infarction associated with cardiomyocyte injury (= cardiac troponin elevation) (2)

Acute neurological event (e.g. stroke or subarachnoid haemorrhage)

Cardiac contusion or cardiac procedures (CABG, PCI, ablation, pacing, cardioversion, or endomyocardial biopsy)

Hypo- and hyperthyroidism

Infiltrative diseases (e.g. amyloidosis, haemochromatosis, sarcoidosis, scleroderma)

Myocardial drug toxicity or poisoning (e.g. doxorubicin, 5-fluorouracil, herceptin, snake venoms)

Extreme endurance efforts


Rhabdomyolysis

Bold = most frequent conditions. ^aIncludes myocardial extension of endocarditis or pericarditis.


ECG Diagnosis

- new ST-segment elevation at the J point in two contiguous leads at (a)
 - ≥ 0.2 mV in ≥ 40 years,
 - ≥ 0.25 mV in men < 40 years
 - ≥ 0.15 mV in women in leads **V2–V3**
- and/ or (b) ≥ 0.1 mV in all other leads


- In women prevalence was 20% and there was no change with aging.
- This is a **NORMAL** finding –not a normal variant.
- ST segment is **CONCAVE** and the deeper the S wave the more the ST elevation.



ST Variants of Normal




- In some healthy young people- especially black men -the ST segment is elevated by 1-4 mm in the mid precordial leads.
- ST elevation is most marked in V4 and there is a notch at the J point.
- ST segment is CONCAVE.
- T waves are tall and not inverted
- May have P-R segment depression (< than in pericarditis)



Persistent juvenile pattern




ANTERIOR STEMI




ANTERIOR STEMI



ANTERIOR STEMI



ANTERIOR STEMI




- Findings in the context of LBBB which should raise clinical suspicion of acute MI include
 1. concordant ST-segment elevation ≥ 1 mm in leads with positive QRS complex
 2. concordant ST-segment depression ≥ 1 mm in V1–V3 and
 3. discordant ST-segment elevation ≥ 5 mm in leads with a negative QRS complex

ANTERIOR STEMI



ANTERIOR STEMI




ANTERIOR STEMI




De Winter's T-Waves / Proximal Left Anterior Descending Artery (LAD) Occlusion


Figure 3.




WELLEN SIGN




INFERIOR STEMI



POSTERIOR STEMI




INFEROPOSTEROLATERAL STEMI



LMCA Occlusion/3-Vessel Disease

Figure 5.



- The presence of reciprocal ST depression helps confirm the diagnosis and differentiates myocardial ischemia from other causes of ST-segment abnormalities, such as left ventricular aneurysm or even noncardiac causes such as subarachnoid hemorrhage

Table 4 Differential diagnoses of acute coronary syndromes in the setting of acute chest pain

Cardiac	Pulmonary	Vascular	Gastro-intestinal	Orthopaedic	Other
Myopericarditis	Pulmonary embolism	Aortic dissection	Oesophagitis, reflux, or spasm	Musculoskeletal disorders	Anxiety disorders
Cardiomyopathies ^a	(Tension)-pneumothorax	Symptomatic aortic aneurysm	Peptic ulcer, gastritis	Chest trauma	Herpes zoster
Tachyarrhythmias	Bronchitis, pneumonia	Stroke	Pancreatitis	Muscle injury/inflammation	Anaemia
Acute heart failure	Pleuritis		Cholecystitis	Costochondritis	
Hypertensive emergencies				Cervical spine pathologies	
Aortic valve stenosis					
Takotsubo syndrome					
Coronary spasm					
Cardiac trauma					

© ESC 2020

Bold = common and/or important differential diagnoses.

^aDilated, hypertrophic and restrictive cardiomyopathies may cause angina or chest discomfort.

© ESC

Prehospital Treatment of Myocardial Infarction

- Prehospital therapy for acute MI focuses on reducing thrombus burden and coagulation cascade hyperactivity prior to coronary reperfusion treatment

Prehospital Treatment of Myocardial Infarction

- current practice are prompt dual antiplatelet therapy in the form of aspirin and a potent P2Y12 inhibitor and an appropriate anticoagulant after assessment of bleeding risk

What is new? New key recommendations (2)

Antithrombotic treatment (continued)

It is not recommended to administer routine pre-treatment with a P2Y₁₂ receptor inhibitor in patients in whom the coronary anatomy is not known and early invasive management is planned.

In patients with NSTEMI-ACS who cannot undergo an early invasive strategy, pre-treatment with a P2Y₁₂ receptor inhibitor may be considered depending on bleeding risk.

De-escalation of P2Y₁₂ inhibitor treatment (e.g. with a switch from prasugrel or ticagrelor to clopidogrel) may be considered as an alternative DAPT strategy, especially for ACS patients deemed unsuitable for potent platelet inhibition. De-escalation may be done unguided based on clinical judgment or guided by platelet function testing or CYP2C19 genotyping depending on the patient's risk profile and availability of respective assays.

Antiplatelet Therapy

- benefits of dual antiplatelet therapy (DAPT) in patients undergoing primary PCI :
- reducing the ongoing and persistent risk of stent thrombosis
- reduces the risk of subsequent spontaneous MI in non-stented coronary segments and all-cause mortality

- aspirin should be administered as soon as possible.
- The dissolved or chewed oral form is preferable with a recommended dose of 150–300 mg.
- intravenous aspirin therapy in the setting of STEMI with dose between 75 and 150 mg is appropriate in patients unable to tolerate the oral route.

Fibrinolytic Therapy

- importance of early administration:
- mortality is more than halved when given less than 2 h from symptom onset compared with later

Fibrinolytic Therapy

- primary PCI is the optimal reperfusion strategy for STEMI patients presenting within 12 h of symptom onset.
- However, the success of any reperfusion strategy is still dependent on total ischemic time.
- Patients should not be delayed with treatment where a primary PCI facility is not within reasonable proximity

Fibrinolytic Therapy

- Fibrinolytic therapy should be administered prehospital (preferably <10 min of STEMI diagnosis) and within 12 h of symptom onset in the absence of contraindications if a primary PCI facility is logistically unavailable

Fibrinolytic Therapy

- Fibrin-specific agents are preferred (e.g. tenecteplase) over systemic lytic agents (e.g. streptokinase) and should be co-administered with age-adjusted doses of dual antiplatelet and anticoagulation therapy

Safe Transfer to the Heart Attack Centre

- defibrillator pads should be routinely attached with continuous cardiac monitoring
- Supplemental oxygen therapy in hypoxemic patients
- sublingual nitroglycerin
- Intravenous morphine